NCT01704859View on ClinicalTrials.gov

VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers

NACompletedINTERVENTIONAL
Enrollment

25,871

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

March 31, 2022

Study Completion Date

November 23, 2022

Conditions
Fractures
Interventions
DIETARY_SUPPLEMENT

Vitamin D3 placebo

Vitamin D placebo

DIETARY_SUPPLEMENT

Fish oil placebo

Fish oil placebo

DRUG

omega-3 fatty acids (fish oil)

Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).

DIETARY_SUPPLEMENT

Vitamin D3

Vitamin D3 (cholecalciferol), 2000 IU per day.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Brigham and Women's Hospital

OTHER

NCT01704859 - VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers | Biotech Hunter | Biotech Hunter